Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472079 | 1.00 | UTS2R (1.00) | UTS2R | |
| SCHEMBL1472243 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472879 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472652 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472228 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472237 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472227 | 0.93 | UTS2R (0.88) | UTS2R | |
| SCHEMBL1472327 | 0.93 | UTS2R (0.87) | UTS2R | |
| SCHEMBL1472393 | 0.92 | UTS2R (0.85) | UTS2R | |
| SCHEMBL1472834 | 0.92 | UTS2R (0.85) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.